Delray Beach, Florida
United States
31
2026-01-15
The entities that hold a legal rights for patent applications filed by inventor Goldenberg David M.:
David M. Goldenberg from Delray Beach, US has applied for patents for these inventions. The list has both pending applications and granted patents:
DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#2 | 2025-10-30NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES
#3 | 2025-10-09ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#4 | 2025-09-18DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#5 | 2024-12-05DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#6 | 2024-12-05Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#7 | 2024-10-24EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS
#8 | 2024-10-24EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS
#9 | 2024-10-24EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS
#10 | 2024-10-24EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS
#11 | 2024-10-24Antibody-drug conjugates and uses thereof
#12 | 2024-06-06THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#13 | 2024-05-09DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#14 | 2024-05-02DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#15 | 2023-07-27ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER
#16 | 2022-02-24ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#17 | 2021-12-23EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS
#18 | 2021-12-23THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#19 | 2021-09-09NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES
#20 | 2021-03-11Antibody-drug conjugates and uses thereof
#21 | 2021-02-18DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#22 | 2020-04-23Immunoconjugates with an intracellularly-cleavable linkage
#23 | 2020-03-19Antibody-drug conjugates and uses thereof
#24 | 2019-12-19Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#25 | 2019-12-05ISOLATION, DETECTION, DIAGNOSIS AND/OR CHARACTERIZATION OF CIRCULATING TROP-2-POSITIVE CANCER CELLS
#26 | 2019-03-21Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#27 | 2019-03-21Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
#28 | 2019-03-07Humanized Anti-HLA-DR Antibodies
#29 | 2019-01-24Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#30 | 2018-11-15Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
#31 | 2018-10-18Nucleic acids encoding chimeric and humanized anti-histone antibodies
2324360 ⎘